

Special Issue

State-of-the-Art Cancer Immunology and Immunotherapy in the USA

Message from the Guest Editors

Cancer remains the top public health burden worldwide. In the United States, an estimated number of new cancer cases is 1,918,030, and 609,360 estimated deaths cases of cancer in 2022. The leading cause of death is lung cancer, with about 350 losses of lives per day. Immunotherapy of cancer has become an important daily clinical practice of cancer treatment in recent decades. However, the partial response from patients, treatment resistance, metastasis, adverse side effects, and even high cost are remaining major concerns during the therapeutic period. These are the urgent issues that need to be overcome. The aim of this Special Issue is to collect high-quality basic research, preclinical research, and clinical research on cancer immunology and immunotherapy articles conducted in the United States or by researchers affiliated and/or cooperated with researchers in the United States. We hope that this Special Issue will highlight state-of-the-art cancer immunology and immunotherapy and promote and raise novel therapeutic strategies against cancer in the USA and worldwide.

Guest Editors

Prof. Dr. Razelle Kurzrock

Dr. Anwaar Saeed

Dr. Linlin Guo

Dr. Ludimila Cavalcante

Deadline for manuscript submissions

closed (20 June 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/130358

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)